Literature DB >> 15882276

Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD.

Francesca Mallamaci1, Giovanni Tripepi, Sebastiano Cutrupi, Lorenzo S Malatino, Carmine Zoccali.   

Abstract

BACKGROUND: Cardiovascular risk stratification is important in the clinical management of patients with end-stage renal diseases (ESRD) and biomarkers are increasingly used in these patients.
METHODS: In a cohort of 246 dialysis patients without heart failure at baseline we tested the combined prognostic power of three well-established biomarkers: brain natriuretic peptide (BNP), C-reactive protein (CRP), and asymmetric dimethyl arginine (ADMA). The independent prognostic value of individual and combined biomarkers was estimated in separate Cox models, including standard risk factors in dialysis patients and comorbidities.
RESULTS: When the prediction power of the three biomarkers was evaluated individually, BNP, ADMA, and CRP added significant predictive value (P< or = 0.01) to all-cause and cardiovascular mortality models and the explanatory gain attributable to these biomarkers were of similar degree (ranging from 3.3% to 5.7%). When the biomarkers were evaluated jointly, a score based on the BNP-CRP combination, increased by 9.9% (all-cause) and by 10.5% (cardiovascular) the explained mortality variance of standard Cox models and such gain in power was similar to that achieved by the CRP-ADMA combination (all-cause death 9.0% and cardiovascular death 8.4%). Of note, the explanatory gain derived by the simultaneous use of the three biomarkers was very similar (all-cause death 11.6% and cardiovascular death 10.5%) to that achieved by the use of two biomarkers.
CONCLUSION: These findings indicate a potential role for CRP, BNP, and ADMA to be incorporated into diagnostic and therapeutic strategies aimed at detection and treatment of atherosclerotic complications and at preventing heart failure in the dialysis population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882276     DOI: 10.1111/j.1523-1755.2005.00338.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  29 in total

Review 1.  Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis.

Authors:  Alberto Ortiz; Ziad A Massy; Danilo Fliser; Bengt Lindholm; Andrzej Wiecek; Alberto Martínez-Castelao; Adrian Covic; David Goldsmith; Gültekin Süleymanlar; Gérard M London; Carmine Zoccali
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

2.  Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine.

Authors:  Clifford L Cua; Lynette K Rogers; Louis G Chicoine; Molly Augustine; Yi Jin; Patricia L Nash; Leif D Nelin
Journal:  Eur J Pediatr       Date:  2010-12-01       Impact factor: 3.183

3.  The relationship of plasma ADMA levels with cardiac functions and metabolic parameters in peritoneal dialysis patients.

Authors:  Savas Ozturk; Serhat Karadag; Metin Yegen; Meltem Gursu; Sami Uzun; Zeki Aydin; Ahmet Gurdal; Macit Koldas; Baki Kumbasar; Rumeyza Kazancioglu
Journal:  Clin Exp Nephrol       Date:  2012-11-27       Impact factor: 2.801

Review 4.  Searching for uremic toxins.

Authors:  Mirela Dobre; Timothy W Meyer; Thomas H Hostetter
Journal:  Clin J Am Soc Nephrol       Date:  2012-09-27       Impact factor: 8.237

5.  Inflammation, kidney function and albuminuria in the Framingham Offspring cohort.

Authors:  Ashish Upadhyay; Martin G Larson; Chao-Yu Guo; Ramachandran S Vasan; Izabella Lipinska; Christopher J O'Donnell; Sekar Kathiresan; James B Meigs; John F Keaney; Jian Rong; Emelia J Benjamin; Caroline S Fox
Journal:  Nephrol Dial Transplant       Date:  2010-08-03       Impact factor: 5.992

Review 6.  Monitoring of inflammation in patients on dialysis: forewarned is forearmed.

Authors:  Christiaan L Meuwese; Peter Stenvinkel; Friedo W Dekker; Juan J Carrero
Journal:  Nat Rev Nephrol       Date:  2011-03       Impact factor: 28.314

7.  Asymmetric and symmetric dimethylarginine concentration as an indicator of cardiovascular diseases in rheumatoid arthritis patients: a systematic review and meta-analysis of case-control studies.

Authors:  Parisa Zafari; Ahmadreza Zarifian; Reza Alizadeh-Navaei; Mahdi Taghadosi; Alireza Rafiei; Zahra Samimi; Fatemeh Niksolat
Journal:  Clin Rheumatol       Date:  2019-08-03       Impact factor: 2.980

8.  Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.

Authors:  P Manghat; W D Fraser; A S Wierzbicki; I Fogelman; D J Goldsmith; G Hampson
Journal:  Osteoporos Int       Date:  2009-12-09       Impact factor: 4.507

9.  Endothelial dysfunction, inflammation and malnutrition markers as predictors of mortality in dialysis patients: multimarker approach.

Authors:  Aleksandra M Ignjatović; Tatjana P Cvetković; Radmila M Pavlović; Vidojko M Đorđević; Zoran G Milošević; Vidosava B Đorđević; Dušica D Pavlović; Ivana R Stojanović; Dragan Bogdanović
Journal:  Int Urol Nephrol       Date:  2013-04-17       Impact factor: 2.370

Review 10.  Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease.

Authors:  Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2008-12-13       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.